£50K is a fair amount of skin to put in ... well done Mo that's agraet vote of confidence.
The prospect of increased efficacy with improved quality of life for IPF patients is a realistic possibility for NXP002 combination therapies based on our existing pilot human IPF tissue data. I am confident that our revised pre-clinical strategy will maximise the value of our IP estate and will generate further compelling data to support both progression and partnering of NXP002. I look forward to providing further updates throughout the remainder of the year."
SOG great research as usual ... The silence is solid and will pay off on the end ... We are due news very soon regards the trial application and news on sar737 or whatever it will be called is likely to land early next month ... not long now and I am certain we will get an offer we cannot refuse ... I am confident that our company is playing hardball with various suiters ... All good things come to those who wait ... LH &K Mafuta
Yes good news indeed ... Market should react positively ... Could be a good day LH&K Mafuta
Rather reminiscent of the time we spiked to 10p (old money) ... I'm happy with the science and TBH I don't read any of the new posts on the science ... But it is essential reading for new investors ... I've said it before if you are unhappy with your investment get out at the first opportunity and invest elsewhere ... moaning about it doesn't help ... You are either happy to wait or not ... Not rocket science really ... As for me I am in the happy position to be able to wait ... sorry for those who aren't ... LH&K Mafuta
https://twitter.com/Edison_Inv_Res/status/1569656621667598336?s=19
Notably this sentence: "The approval of Sotyktu was widely expected and validates the potential of this new asset class, in our opinion. Sareum asserts that SDC-1801’s dual targeting could potentially accord superior efficacy, which if proved could translate to a sizeable market opportunity for Sareum."
We're encouraged that the FDA has approved Sotyktu (deucravacitinib)," said Tim Mitchell, CEO of Sareum. "We believe this validates the potential of this new therapeutic class and supports our own growing confidence around our lead programme and our broader portfolio of TYK2/JAK1 inhibitors
Yes thanks great summary ... Much appreciated
Actually the sun does shine on the "dark" side of the moon. ... But on earth we don't get to see it. ... However I guess nobody asked for a lesson on astronomy ... Still waiting for 'when the boat comes in"... LH&K Mafuta
Results Inhaled NXP002 was wel tolerated, with no inflammatory response observed. Dose-dependent increases of NXP002 in lung tissue and BAL were observed, equivalent to or higher than following oral administration despite lower plasma levels. Inhaled NXP002 resulted in a dose-dependent decrease in LPS-induced BAL cell count, which was less than that seen folowing oral delivery. Despite this, inhaled delivery resulted in a greater reduction in LPS-induced BAL mediators, including MCP-1 and TGFß. This study demonstrates that inhaled NXP002 is well tolerated. Inhaled delivery has a superior effect on fibrosis related mediators whilst having a reduced systemic exposure than oral dosing.
Now someone has to sit up and notice. LH&K Mafuta